Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$97.75 USD

97.75
409,224

+0.17 (0.17%)

Updated Jul 25, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Brookdale Senior Living, The Ensign Group, Amedysis and Chemed

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Brookdale Senior Living, The Ensign Group, Amedysis and Chemed

Aparajita Dutta headshot

Silver Tsunami to Hit the United States: 4 Stocks in Focus

by Aparajita Dutta

There are approximately 35 million Americans aged 65 or older currently and this number is expected to double in the next 25 years.

Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

by Zacks Equity Research

Sector ETF report for PTH

Amedisys (AMED) Q1 Earnings Beat, Operating Margin Falls

by Zacks Equity Research

Amedisys (AMED) notes that COVID-19 started impacting its volumes and costs beginning the second half of March.

Amedisys (AMED) Beats Q1 Earnings Estimates

by Zacks Equity Research

Amedisys (AMED) delivered earnings and revenue surprises of 8.25% and -4.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks.com featured highlights include: Vertex Pharmaceuticals, Alibaba, Amedisys and Fabrinet

by Zacks Equity Research

Zacks.com featured highlights include: Vertex Pharmaceuticals, Alibaba, Amedisys and Fabrinet

Sumit Singh headshot

Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio

by Sumit Singh

Interest Coverage Ratio suggests how many times the interest could be paid from earnings and gauges the margin of safety a firm has for paying interest.

Zacks.com featured highlights include: NEE, FNV, AMED, ATO and COST

by Zacks Equity Research

Zacks.com featured highlights include: NEE, FNV, AMED, ATO and COST

Bet on These 5 Low Leverage Stocks to Avoid Huge Losses

by Zacks Equity Research

With the earnings season in full swing, the real challenge for an investor is determining whether an organization's debt level is sustainable.

Earnings Preview: Amedisys (AMED) Q1 Earnings Expected to Decline

by Zacks Equity Research

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)

by Zacks Equity Research

Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Quest Diagnostics (DGX) in Focus: Stock Moves 5.4% Higher

by Zacks Equity Research

Quest Diagnostics (DGX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Sumit Singh headshot

Add These 4 Stocks With Remarkable Interest Coverage Ratio

by Sumit Singh

Debt, which is crucial for most of the companies to finance operations, comes at a cost called interest. Interest expense has a direct bearing on the profits of a company.

Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AMED) Outperforming Other Medical Stocks This Year?

Bet on These 5 Low Leverage Stocks as Q1 Earnings Starts

by Zacks Equity Research

To safeguard one's portfolio from notable losses, the real challenge for an investor is determining whether the organization's debt level is sustainable. A debt-free corporation is hard to find.

Amedisys (AMED) Is Up 8.62% in One Week: What You Should Know

by Zacks Equity Research

Does Amedisys (AMED) have what it takes to be a top stock pick for momentum investors? Let's find out.

Amedisys (AMED) Upgraded to Buy: Here's Why

by Zacks Equity Research

Amedisys (AMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Amedisys (AMED) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Amedisys (AMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Amedisys Gains on Expanding Hospice Arm, Favorable Demography

by Zacks Equity Research

Amedisys' (AMED) recent acquisitions in the Hospice arm aid the company's growth.

Amedisys (AMED) Stock Moves -0.87%: What You Should Know

by Zacks Equity Research

In the latest trading session, Amedisys (AMED) closed at $168.20, marking a -0.87% move from the previous day.

Here's Why You Should Retain Amedisys (AMED) Stock for Now

by Zacks Equity Research

Investor confidence is high in Amedisys (AMED) stock, thanks to solid prospects.

Why Is Amedisys (AMED) Down 16.2% Since Last Earnings Report?

by Zacks Equity Research

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain LHC Group (LHCG) Stock Now

by Zacks Equity Research

LHC Group (LHCG) continues to benefit from broad array of services and inorganic expansion. However, intense competition remains a woe.

Sumit Singh headshot

Scoop Up These 5 Promising Interest Coverage Ratio Stocks

by Sumit Singh

Interest expense has a direct bearing on the profits of a company and the company's creditworthiness depends on how effectively it meets its interest obligations.

Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AMED) Outperforming Other Medical Stocks This Year?